FANJ
PLX icon

Financial Architects (New Jersey)’s Protalix BioTherapeutics PLX Stock Holding History

Financial Architects (New Jersey)’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-1,000
Closed -$6K – 1473
2016
Q3 		$6K Hold
1,000
– – ﹤0.01% 1114
2016
Q2 		$6K Hold
1,000
– – ﹤0.01% 1087
2016
Q1 		$8K Buy
+1,000
New +$8.57K ﹤0.01% 805

Other funds holding PLX

HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
AGC
Angelo Gordon & Co New York $1.06B AUM 47.95% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Financial Architects (New Jersey)'s PLX Position: Q4 2016 in Review

Financial Architects (New Jersey) sold out of Protalix BioTherapeutics (PLX) in Q4 2016, closing a stake of 1,000 shares — an estimated $6K sold.

Financial Architects (New Jersey) first reported a position in PLX in Q1 2016 and held it in 3 quarters. The position peaked at $8K in Q1 2016. 33 funds tracked by Wall St. Rank hold PLX as of Q4 2016.

  • Financial Architects (New Jersey) reported no remaining Protalix BioTherapeutics position as of Q4 2016 after selling out during the quarter.
  • Financial Architects (New Jersey) sold 1,000 Protalix BioTherapeutics shares in Q4 2016, an estimated $6K.
  • Financial Architects (New Jersey) first reported a position in Protalix BioTherapeutics in Q1 2016 and held it in 3 quarters.
  • Financial Architects (New Jersey)'s Protalix BioTherapeutics position peaked at $8K in Q1 2016.
  • 33 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q4 2016.

Based on Financial Architects (New Jersey)'s 13F filing for Q4 2016, filed 6 Feb 2017.